524500 Stock Overview
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Kilitch Drugs (India) Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹349.05 |
| 52 Week High | ₹469.85 |
| 52 Week Low | ₹157.00 |
| Beta | 0.31 |
| 1 Month Change | -4.59% |
| 3 Month Change | -13.01% |
| 1 Year Change | 102.94% |
| 3 Year Change | 222.75% |
| 5 Year Change | 86.36% |
| Change since IPO | 14,753.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| 524500 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.3% | -0.5% | 1.4% |
| 1Y | 102.9% | 55.3% | 46.1% |
Return vs Industry: 524500 exceeded the Indian Pharmaceuticals industry which returned 53.7% over the past year.
Return vs Market: 524500 exceeded the Indian Market which returned 45% over the past year.
Price Volatility
| 524500 volatility | |
|---|---|
| 524500 Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 524500's share price has been volatile over the past 3 months.
Volatility Over Time: 524500's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 153 | Mukund Mehta | www.kilitch.com |
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of liquid ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products.
Kilitch Drugs (India) Limited Fundamentals Summary
| 524500 fundamental statistics | |
|---|---|
| Market cap | ₹5.61b |
| Earnings (TTM) | ₹145.71m |
| Revenue (TTM) | ₹1.55b |
38.5x
P/E Ratio3.6x
P/S RatioIs 524500 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524500 income statement (TTM) | |
|---|---|
| Revenue | ₹1.55b |
| Cost of Revenue | ₹804.09m |
| Gross Profit | ₹746.22m |
| Other Expenses | ₹600.52m |
| Earnings | ₹145.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 30, 2024
| Earnings per share (EPS) | 9.06 |
| Gross Margin | 48.13% |
| Net Profit Margin | 9.40% |
| Debt/Equity Ratio | 17.2% |
How did 524500 perform over the long term?
See historical performance and comparison